Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma - Inserm - Institut national de la santé et de la recherche médicale
Article Dans Une Revue Journal for Immunotherapy of Cancer Année : 2020

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

1 INT-FGP - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy]
2 IRCCS Istituto Nazionale dei Tumori [Milano]
3 PUMS - Poznan University of Medical Sciences [Poland]
4 IGR - Institut Gustave Roussy
5 UP11 - Université Paris-Sud - Paris 11
6 Oncologie dermatologique
7 Istituto Oncologico Veneto I.R.C.C.S. [Padova, Italy]
8 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
9 CIC-1427 - CIC Saint Louis
10 AP-HP - Hopital Saint-Louis [AP-HP]
11 Herlev and Gentofte Hospital
12 Copenhagen University Hospital
13 RPAH - Royal Prince Alfred Hospital [Camperdown, Australia]
14 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
15 University Medical Center [Mainz]
16 OncoThAI - Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
17 Hôpital Claude Huriez [Lille]
18 OUH - Odense University Hospital
19 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
20 AöR - University Hospital Essen
21 DKTK - German Cancer Consortium [Heidelberg]
22 Eberhard Karls Universität Tübingen = University of Tübingen
23 Oslo University Hospital [Oslo]
24 AMU - Aix Marseille Université
25 APHM - Assistance Publique - Hôpitaux de Marseille
26 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
27 National Institute of Oncology [Budapest, Hungary]
28 Cross Cancer Institute [Edmonton, AB, Canada]
29 Medizinische Universität Wien = Medical University of Vienna
30 Regina Elena National Cancer Institute [Rome]
31 CHU Reims - Hôpital universitaire Robert Debré [Reims]
32 MHH - Medizinische Hochschule Hannover = Hannover Medical School
33 Wojewodzkie Centrum Oncologii [Gdańsk, Poland]
34 Bristol-Myers Squibb [Princeton]
35 University Hospital of Siena
Omid Hamid
  • Fonction : Auteur

Résumé

Background: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. Methods: This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS. Results: At a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 months (95% CI 9.9 to 13.3) at 3 mg/kg (HR 0.84, 95% CI 0.71 to 0.99; p=0.04). In a subgroup analysis, median OS of patients with asymptomatic brain metastasis was 7.0 months (95% CI 4.0 to 12.8) in the 10 mg/kg group and 5.7 months (95% CI 4.2 to 7.0) in the 3 mg/kg group. In patients with wild-type or mutant BRAF tumors, median OS was 13.8 months (95% CI 10.2 to 17.0) and 33.2 months (95% CI 19.4 to 45.2) in the 10 mg/kg group, and 11.2 months (95% CI 9.2 to 13.8) and 19.7 months (95% CI 11.6 to 25.3) in the 3 mg/kg group, respectively. The incidence of grade 3/4 treatment-related AEs was 36% in the 10 mg/kg group vs 20% in the 3 mg/kg group, and deaths due to treatment-related AEs occurred in four (1%) and two patients (1%), respectively. Conclusions: This 61-month follow-up of a phase III trial showed sustained long-term survival in patients with advanced melanoma who started metastatic treatment with ipilimumab monotherapy, and confirmed the significant benefit for those who received ipilimumab 10 mg/kg vs 3 mg/kg. These results suggest the emergence of a plateau in the OS curve, consistent with previous ipilimumab studies.
Fichier principal
Vignette du fichier
e000391.full.pdf (1.93 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

inserm-03709901 , version 1 (30-06-2022)

Identifiants

Citer

Paolo Antonio Ascierto, Michelle del Vecchio, Andrzej Mackiewicz, Caroline Robert, Vanna Chiarion-Sileni, et al.. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩. ⟨inserm-03709901⟩
28 Consultations
41 Téléchargements

Altmetric

Partager

More